<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Sci Rep</journal-id><journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id><journal-title-group><journal-title>Scientific Reports</journal-title></journal-title-group><issn pub-type="epub">2045-2322</issn><publisher><publisher-name>Nature Publishing Group UK</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28900096</article-id><article-id pub-id-type="pmc">5595810</article-id><article-id pub-id-type="publisher-id">9676</article-id><article-id pub-id-type="doi">10.1038/s41598-017-09676-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Comparison of quality of life between Billroth-&#x00406; and Roux-en-Y anastomosis after distal gastrectomy for gastric cancer: A randomized controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Yang</surname><given-names>Kun</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Zhang</surname><given-names>Wei-Han</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Kai</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Xin-Zu</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Zong-Guang</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Hu</surname><given-names>Jian-Kun</given-names></name><address><email>hujkwch@126.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label>Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu, China </aff><aff id="Aff2"><label>2</label>Laboratory of Gastric Cancer, State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China </aff></contrib-group><pub-date pub-type="epub"><day>12</day><month>9</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>12</day><month>9</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>7</volume><elocation-id>11245</elocation-id><history><date date-type="received"><day>25</day><month>1</month><year>2017</year></date><date date-type="accepted"><day>28</day><month>7</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Studies comparing Billroth-I (B-I) with Roux-en-Y (R-Y) anastomosis are still lacking and inconsistent. The aim of this trial was to compare the quality of life (QoL) of B-I with R-Y reconstruction after curative distal gastrectomy for gastric cancer. A total of 140 patients were randomly assigned to the B-I group (N&#x02009;=&#x02009;70) and R-Y group (N&#x02009;=&#x02009;70) with the comparable baseline characteristics. The overall postoperative morbidity rates were 18.6% and 25.7% in the B-I group and R-Y group without significant difference. More estimated blood loss and longer surgical duration were found in the R-Y group. At the postoperative 1 year time point, the B-I group had a higher score in pain, but lower score in global health. However, the R-Y anastomosis was associated with lower incidence of reflux symptoms at postoperative 6 months (P&#x02009;=&#x02009;0.002) and postoperative 9 months (P&#x02009;=&#x02009;0.007). The multivariable analyses of variance did not show any interactions between the time trend and grouping. For the results of endoscopic examination, the degree and extent of remnant gastritis were milder significantly in the R-Y group. The stronger anti-reflux capability of R-Y anastomosis contributes to the higher QoL by reducing the reflux related gastritis and pain symptoms, and promotes a better global health.</p></abstract><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par2">Gastric cancer remains a disease with high incidence and is responsible for about 10% of all cancer-related deaths in the world<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. Although the incidence of gastric cancer at the upper third of stomach has gradually increased over the years, distal gastric cancers as well as distal gastrectomy are still the mainstream<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>. In recent years, the overall survival of patients with gastric cancer has improved as the increase of proportion of early gastric cancer detection, the implementation of standard D2 lymphadenectomy, the development of chemotherapy and new targeted drugs<sup><xref ref-type="bibr" rid="CR3">3</xref>&#x02013;<xref ref-type="bibr" rid="CR5">5</xref></sup>. Accompanied with the improved survival, the quality of life (QoL) has attracted more attentions than before. One of the most associated factors with QoL of patients after gastrectomy is the type of digestive tract reconstruction.</p><p id="Par3">Billroth-I (B-I) and Roux-en-Y (R-Y) reconstruction after distal gastrectomy have been widely applied. Both B-I and R-Y have their own advantages and disadvantages. B-I has merits of technical simplicity and preservation of physiological food passage. However, patients undergoing B-I reconstruction frequently suffer from the reflux symptoms, which could cause remnant gastritis and esophagitis, even increase the possibility of remnant gastric cancer or esophageal cancer<sup><xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref></sup>. In the contrast, R-Y reconstruction has strong capacity to prevent bile reflux theoretically<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>. Nevertheless, patients with R-Y reconstruction often complain so-called stasis syndrome, which has the significant postoperative symptoms including abdominal pain, nausea, and vomiting<sup><xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref></sup>. Furthermore, the difficulty of postoperative duodenal endoscopic examination makes surgeons reluctant to perform R-Y reconstruction.</p><p id="Par4">Currently, although a few studies have compared the morbidity, mortality and QoL of B-I with R-Y anastomosis, their findings are still inconsistent<sup><xref ref-type="bibr" rid="CR11">11</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref></sup>. Moreover, most of the studies which compared B-I with R-Y anastomosis were carried out in Japan and Korea where the proportions of early gastric cancer are more than 50%<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>. Therefore, the generalizability of such evidence to other countries where most of the patients has advanced gastric cancer still needs addressing. In addition, there was no study to dynamically compare the QoL of B-I with R-Y reconstruction by standard questionnaires at multiple time points.</p><p id="Par5">Therefore, we performed a prospective randomized controlled trial (RCT) to compare B-I with R-Y reconstruction after curative distal gastrectomy for gastric cancer in China. Here, we reported the results of 1-year interim analysis.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Materials and Methods</title><sec id="Sec3"><title>Patients</title><p id="Par6">The inclusion criteria were the following: patients aged 18 to 75 with tolerance of the operation; the score of World Health Organization performance status being less than 2; preoperative diagnosis of gastric adenocarcinoma was confirmed by gastric endoscopy and biopsy; the tumors located at lower third of stomach for which distal gastrectomy was feasible; the preoperative staging of potential curative resectable tumors was less than T4aN2M0 according to the 3<sup>rd</sup> English edition of Japanese Classification of Gastric Carcinoma<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>; either open gastrectomy or laparoscopic assisted gastrectomy was included. The exclusion criteria consisted of: patients with history of previous laparotomy (except appendectomy and laparoscopic cholecystectomy); patients needed receiving total gastrectomy or combined organ resection (except cholecystectomy) for curative purpose; patients were diagnosed with other gastric malignances, such as lymphoma and gastrointestinal stromal tumor <italic>etc</italic>, any previous malignancies or synchronous malignancies; emergency cases because of perforation or bleeding of tumor; patients had neo-adjuvant chemotherapy or perioperative radiotherapy.</p><p id="Par7">This study was registered on Chinese Clinical Trial Register (ChiCTR), WHO (SN. ChiCTR-TRC-10001434, date of registration: November 24<sup>th</sup>, 2010), and approved by the West China Hospital research ethics committee, and the study was done in accordance with the Declaration of Helsinki. Written informed consent were obtained from all patients.</p></sec><sec id="Sec4"><title>Study design</title><p id="Par8">After being generated by random number table, the random allocation sequence was concealed and sealed in sequential numbered and opaque envelopes, which were uncovered following the initial laparotomy to assess the eligibility of patients. Then, included patients were randomly assigned to the B-I or R-Y group in a 1:1 ratio intraoperatively. In this study, patients, surgeons, staffs who collected data and analyzed outcomes were not blinded. During the study period, the study protocol was not amended.</p></sec><sec id="Sec5"><title>Surgical technique</title><p id="Par9">The nasogastric tube was placed routinely before the operation. All the patients underwent distal gastrectomy with D2 lymphadenectomy according to the Japanese gastric cancer treatment guideline<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>. All the anastomoses were completed by using the mechanical staplers and reinforced by interrupted full-thickness sutures. Briefly, the end-to-side gastroduodenostomy was made by 25&#x02009;mm circular stapler between the duodenal stump and posterior wall of the remnant stomach in the B-I group. And the gastric stump was closed by linear stapler. In the R-Y group, the duodenum was divided and closed by a linear stapler 3&#x02009;cm distal to the pylorus. Then, the duodenal stump was reinforced by interrupted full-thickness sutures and interrupted seromuscular sutures. For reconstruction, the proximal jejunum was identified and divided 15&#x02013;20&#x02009;cm distant from the Treitz ligament firstly. Next, the gastrojejunostomy was performed between posterior wall of the remnant stomach and antimesenteric border of the distal jejunums with a 25&#x02009;mm circular stapler in a side-to side fashion. Then, a side-to-side jejunojejunostomy was created between the antimesenteric borders of the proximal and distal jejunums 45&#x02009;cm below the gastrojejunostomy. The gastric stump and two jejunal stumps were closed by linear staplers. The mesenteric defect was closed with interrupted sutures.</p><p id="Par10">In the patients who received laparoscopic surgery, we performed laparoscopic assisted distal gastrectomy. After the lymph nodes dissection by using laparoscopy, a mini-incision at length of 5&#x02013;8&#x02009;cm was made above the umbilicus. Then specimen was removed and extracorporeal digestive tract reconstruction was performed through the incision. The procedures and staplers used for specimen removal and anastomosis were as same as the open cases.</p><p id="Par11">The drain was also placed routinely through the Winslow foramen. All the surgeons adhered with the protocol. The adherence and the quality of operation were evaluated by the study group through scanning the intraoperative photos.</p></sec><sec id="Sec6"><title>Postoperative care protocol</title><p id="Par12">After the operation, a standardized postoperative care protocol was applied. Intravenous antibiotic prophylaxis and parenteral nutritional support were given to all patients. The nasogastric tube was removed after the first gas-passing, and sips of water started thereafter. Liquid diet and soft diet were given over the next 2 days gradually. The drain was usually removed on postoperative day 5 if there were no complications. If there was no complications after 1&#x02009;day of soft diet, discharge of patients was encouraged. If there were any compilations, treatments were given individually.</p></sec><sec id="Sec7"><title>Outcome measurements</title><p id="Par13">The primary end point of this RCT was QoL. The data of QoL was collected by the validated European Organization for Research and Treatment of Cancer (EORTC) core questionnaire (EORTC QLQ-C30, version 3.0), and stomach module questionnaire (EORTC QLQ-STO22)<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>. The EORTC QLQ-C30 questionnaire contains 30 items, which could be used to assess the QoL of all kinds of cancer patients. The 30 items could be incorporated into five functional scales (physical, role, cognitive, emotional, and social), three symptom scales (pain, fatigue, nausea and vomiting), six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea and financial difficult) and one global health status scale. Except for the global health scale in which the item values range from 1 to 7, other items are scored 1 to 4, corresponding to the four response categories, namely &#x0201c;Not at all&#x0201d;, &#x0201c;A little&#x0201d;, &#x0201c;Quite a bit&#x0201d; and &#x0201c;Very much&#x0201d;<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>. The EORTC QLQ-STO22 questionnaire comprises 22 items, which could be divided into five symptom scales (dysphagia, pain, eating restrictions, reflux symptoms, and anxiety) and four single items (having a dry mouth, taste, body image, and hair loss)<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>. A high score represents a high/healthy level of functioning or QoL for a functional scale or the global health status; whereas a high level of symptomatology/problems for symptom scales/items<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>. The preoperative baseline of QoL was obtained 3 days before the operation. Postoperative QoL, recurrence and survival status were collected every 3 months after the operation by telephone calls, letters or outpatient visits. No patient was lost to follow-up.</p><p id="Par14">The secondary end points were operative safety, postoperative recovery and severity of postoperative gastritis. Clinicopathologic terminology was based on the 3<sup>rd</sup> English edition of Japanese Classification of Gastric Carcinoma<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>. Morbidity, spectrum of complications and mortality were compared. The complications were classified according to the Clavien-Dindo Classification<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>. The estimated blood loss, operative duration, postoperative hospital stay, mean time to the first flatus and mean time to the first food intake were also compared. The severity of postoperative gastritis was evaluated by endoscopic examination at postoperative 12 months and graded according to the &#x0201c;residue, gastritis, bile&#x0201d; classification<sup><xref ref-type="bibr" rid="CR24">24</xref></sup>.</p></sec><sec id="Sec8"><title>Statistical analyses</title><p id="Par15">The sample size was calculated by using a two-sided alpha error of 5% under the normal distribution with a standard deviation of 0.1. And the effect size was determined according to Kojima&#x02019;s study which showed that the heartburn rates of the B-I group and R-Y group were 37% and 8% at the postoperative 1 year respectively<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>. The planned sample size was calculated as 56 in each arm. Finally, we enrolled 70 patients in each arm, allowing for a 15&#x02013;20% dropout rate.</p><p id="Par16">SPSS 19.0 software (SPSS, Chicago, IL, USA) was used for statistical analysis. All QLQ-C30 and QLQ-STO22 responses were linearly transformed to scores from 0 to 100 according to EORTC scoring manuals<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>. Quantitative data was expressed as means&#x02009;&#x000b1;&#x02009;standard deviation (SD) and tested by One-way ANOVA test. For categorical data, the Chi-square was used to compare frequencies. Non-parametric tests were performed for non-normal distribution data. Multivariable analysis of variance was applied to investigate the interaction of time and grouping. A P value of less than 0.05 (two-sided) was considered statistically significant. An intention-to-treat analysis was applied as the main statistical method to avoid potential biases.</p></sec></sec><sec id="Sec9" sec-type="results"><title>Results</title><sec id="Sec10"><title>Characteristics of patients</title><p id="Par17">From May, 2011 to May, 2014, a total of 140 gastric cancer patients who underwent distal gastrectomy were randomly assigned to the B-I group (N&#x02009;=&#x02009;70) and R-Y group (N&#x02009;=&#x02009;70). In B-I group, there were 6 patients converting to the R-Y anastomosis because of the presence of tension between the duodenum and remnant stomach. In R-Y group, 6 patients underwent the B-I anastomosis due to the willingness or economical consideration of patients&#x02019; families. As of postoperative 1 year, 2 patients in the B-I group and 1 patient in the R-Y group recurred, 1 patient in the R-Y group died due to chemotherapy associated hepatic failure. Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> shows the trial profile. The baseline characteristics of patients were comparable between the two groups (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>).<fig id="Fig1"><label>Figure 1</label><caption><p>Trial profile.</p></caption><graphic xlink:href="41598_2017_9676_Fig1_HTML" id="d29e402"/></fig>
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Clinicopathological characteristics of patients in the two groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variables</th><th>B-I group N&#x02009;=&#x02009;70 (%)</th><th>R-Y group N&#x02009;=&#x02009;70 (%)</th><th>P Value</th></tr></thead><tbody><tr><td>
<bold>Gender</bold>
</td><td/><td/><td>0.223</td></tr><tr><td>&#x000a0;&#x000a0;Male</td><td>40 (57.1)</td><td>47 (67.1)</td><td rowspan="2"/></tr><tr><td>&#x000a0;&#x000a0;Female</td><td>30 (42.9)</td><td>23 (32.9)</td></tr><tr><td>
<bold>Age</bold>
</td><td>56.3&#x02009;&#x000b1;&#x02009;10.7</td><td>54.9&#x02009;&#x000b1;&#x02009;11.5</td><td>0.491</td></tr><tr><td>
<bold>Educational Level</bold>
</td><td/><td/><td>0.111</td></tr><tr><td>&#x000a0;&#x000a0;&#x0003c;7 years</td><td>26 (37.1)</td><td>17 (24.3)</td><td rowspan="3"/></tr><tr><td>&#x000a0;&#x000a0;7&#x02013;12 years</td><td>29 (41.4)</td><td>28 (40.0)</td></tr><tr><td>&#x000a0;&#x000a0;&#x0003e;12 years</td><td>15 (21.4)</td><td>25 (35.7)</td></tr><tr><td>
<bold>BMI (kg/m2)</bold>
</td><td>22.4&#x02009;&#x000b1;&#x02009;3.1</td><td>22.7&#x02009;&#x000b1;&#x02009;3.5</td><td>0.616</td></tr><tr><td>
<bold>Tumor size (cm)</bold>
</td><td>3.6&#x02009;&#x000b1;&#x02009;1.9</td><td>4.4&#x02009;&#x000b1;&#x02009;2.6</td><td>0.156</td></tr><tr><td>
<bold>Macroscopic type</bold>
</td><td/><td/><td>0.338</td></tr><tr><td>&#x000a0;&#x000a0;Type 0-2</td><td>54 (77.1)</td><td>49 (70.0)</td><td rowspan="2"/></tr><tr><td>&#x000a0;&#x000a0;Type 3-4</td><td>16 (22.9)</td><td>21 (30.0)</td></tr><tr><td>
<bold>Histologic Type</bold>
</td><td/><td/><td>0.494</td></tr><tr><td>&#x000a0;&#x000a0;Well and Moderate differentiated</td><td>13 (18.6)</td><td>10 (14.3)</td><td/></tr><tr><td>&#x000a0;&#x000a0;Poor and undifferentiated</td><td>57 (81.4)</td><td>60 (85.7)</td><td/></tr><tr><td>
<bold>Lauren classification</bold>
</td><td/><td/><td>0.178</td></tr><tr><td>&#x000a0;&#x000a0;Intestinal type</td><td>27 (38.6)</td><td>22 (31.4)</td><td rowspan="3"/></tr><tr><td>&#x000a0;&#x000a0;Diffuse type</td><td>38 (54.3)</td><td>36 (51.4)</td></tr><tr><td>&#x000a0;&#x000a0;Mixed type</td><td>5 (7.1)</td><td>12 (17.1)</td></tr><tr><td>
<bold>Surgical Type</bold>
</td><td/><td/><td>0.699</td></tr><tr><td>&#x000a0;&#x000a0;Open Surgery</td><td>53 (75.7)</td><td>51 (72.9)</td><td rowspan="2"/></tr><tr><td>&#x000a0;&#x000a0;Laparoscopic Surgery</td><td>17 (24.3)</td><td>19 (27.1)</td></tr><tr><td>
<bold>No. of positive LNs</bold>
</td><td>4.6&#x02009;&#x000b1;&#x02009;7.6</td><td>4.6&#x02009;&#x000b1;&#x02009;7.0</td><td>0.917</td></tr><tr><td>
<bold>No. of examined LNs</bold>
</td><td>32.9&#x02009;&#x000b1;&#x02009;12.5</td><td>36.6&#x02009;&#x000b1;&#x02009;18.2</td><td>0.173</td></tr><tr><td>
<bold>Depth of invasion</bold>
</td><td/><td/><td>0.303</td></tr><tr><td>&#x000a0;&#x000a0;T1</td><td>27 (38.6)</td><td>22 (31.4)</td><td rowspan="3"/></tr><tr><td>&#x000a0;&#x000a0;T2</td><td>12 (17.1)</td><td>11 (15.7)</td></tr><tr><td>&#x000a0;&#x000a0;T3/ T4</td><td>31 (44.3)</td><td>37 (52.9)</td></tr><tr><td>
<bold>Lymph nodes metastasis</bold>
</td><td/><td/><td>0.764</td></tr><tr><td>&#x000a0;&#x000a0;N0</td><td>27 (38.6)</td><td>30 (42.9)</td><td rowspan="4"/></tr><tr><td>&#x000a0;&#x000a0;N1</td><td>13 (18.6)</td><td>10 (14.3)</td></tr><tr><td>&#x000a0;&#x000a0;N2</td><td>15 (21.4)</td><td>12 (17.1)</td></tr><tr><td>&#x000a0;&#x000a0;N3</td><td>15 (21.4)</td><td>18 (25.7)</td></tr><tr><td>
<bold>TNM stage</bold>
</td><td/><td/><td>0.237</td></tr><tr><td>&#x000a0;&#x000a0;IA</td><td>18 (25.7)</td><td>13 (18.6)</td><td rowspan="8"/></tr><tr><td>&#x000a0;&#x000a0;IB</td><td>12 (17.1)</td><td>9 (12.9)</td></tr><tr><td>&#x000a0;&#x000a0;IIA</td><td>8 (11.4)</td><td>8 (11.4)</td></tr><tr><td>&#x000a0;&#x000a0;IIB</td><td>6 (8.6)</td><td>11 (15.7)</td></tr><tr><td>&#x000a0;&#x000a0;IIIA</td><td>10 (14.3)</td><td>6 (8.6)</td></tr><tr><td>&#x000a0;&#x000a0;IIIB</td><td>3 (4.3)</td><td>10 (14.3)</td></tr><tr><td>&#x000a0;&#x000a0;IIIC</td><td>10 (14.3)</td><td>9 (12.9)</td></tr><tr><td>&#x000a0;&#x000a0;IV</td><td>3 (4.3)</td><td>4 (5.7)</td></tr><tr><td>
<bold>Adjuvant Chemotherapy</bold>
</td><td/><td/><td>0.062</td></tr><tr><td>&#x000a0;&#x000a0;No</td><td>37 (52.9)</td><td>26 (37.1)</td><td rowspan="2"/></tr><tr><td>&#x000a0;&#x000a0;Yes</td><td>33 (47.1)</td><td>44 (62.9)</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec11"><title>Operative variable and Postoperative recovery</title><p id="Par18">There was no perioperative mortality. The overall postoperative morbidity rates were 18.6% (13/70) and 25.7% (18/70) in the B-I group and R-Y group without significant difference (P&#x02009;=&#x02009;0.309). Postoperative pulmonary infection was the most frequent complication in both groups. There was no anastomosis-related complications. The constitution of complications between the two groups had no significant difference. The estimated blood loss and surgical duration were significantly less in the B-I group. There were no significant differences in terms of postoperative hospital stay, time to first gas-passing, time to first oral intake, time to nasogastric decompression removal and time to drain removal between the two groups. The details can be seen in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Operative safety and postoperative recovery between the two groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>B-I group N&#x02009;=&#x02009;70 (%)</th><th>R-Y group N&#x02009;=&#x02009;70 (%)</th><th>P Value</th></tr></thead><tbody><tr><td>Mortality</td><td>0</td><td>0</td><td>1.000</td></tr><tr><td>Morbidity</td><td>13 (18.6)</td><td>18 (25.7)</td><td>0.309</td></tr><tr><td>Clavien-Dindo classification</td><td/><td/><td>0.921</td></tr><tr><td>&#x000a0;I</td><td>2 (15.4)</td><td>4 (22.2)</td><td/></tr><tr><td>&#x000a0;II</td><td>11 (84.6)</td><td>13 (72.2)</td><td/></tr><tr><td>&#x000a0;IIIa</td><td>0</td><td>0</td><td/></tr><tr><td>&#x000a0;IIIb</td><td>0</td><td>1 (5.6)</td><td/></tr><tr><td>&#x000a0;IVa</td><td>0</td><td>0</td><td/></tr><tr><td>&#x000a0;IVb</td><td>0</td><td>0</td><td/></tr><tr><td>&#x000a0;V</td><td>0</td><td>0</td><td/></tr><tr><td colspan="4">Postoperative Complications</td></tr><tr><td>&#x000a0;Pulmonary complications</td><td>10</td><td>10</td><td>1.000</td></tr><tr><td>&#x000a0;Acute cholecystitis</td><td>1</td><td>1</td><td>1.000</td></tr><tr><td>&#x000a0;Superficial surgical site infection</td><td>0</td><td>2</td><td>0.496</td></tr><tr><td>&#x000a0;Intra-abdominal infection</td><td>0</td><td>2</td><td>0.496</td></tr><tr><td>&#x000a0;Adhesive ileus</td><td>0</td><td>1</td><td>1.000</td></tr><tr><td>&#x000a0;Acute urinary retention</td><td>1</td><td>1</td><td>1.000</td></tr><tr><td>&#x000a0;Gastroplegia</td><td>1</td><td>1</td><td>1.000</td></tr><tr><td>Surgical duration (min)</td><td>239.4&#x02009;&#x000b1;&#x02009;40.8</td><td>271.2&#x02009;&#x000b1;&#x02009;39.2</td><td>&#x0003c;0.001</td></tr><tr><td>Estimated blood loss (ml)</td><td>84.1&#x02009;&#x000b1;&#x02009;32.0</td><td>104.2&#x02009;&#x000b1;&#x02009;35.3</td><td>&#x0003c;0.001</td></tr><tr><td>Postoperative hospital stay (days)</td><td>9.6&#x02009;&#x000b1;&#x02009;1.2</td><td>10.3&#x02009;&#x000b1;&#x02009;3.7</td><td>0.674</td></tr><tr><td>Time to nasogastric tube removal (days)</td><td>4.3&#x02009;&#x000b1;&#x02009;1.4</td><td>4.3&#x02009;&#x000b1;&#x02009;1.3</td><td>0.936</td></tr><tr><td>Time to drain removal (days)</td><td>6.9&#x02009;&#x000b1;&#x02009;1.2</td><td>7.6&#x02009;&#x000b1;&#x02009;3.8</td><td>0.227</td></tr><tr><td>Time to first gas-passing (days)</td><td>4.7&#x02009;&#x000b1;&#x02009;1.1</td><td>4.6&#x02009;&#x000b1;&#x02009;0.9</td><td>0.724</td></tr><tr><td>Time to first oral intake (days)</td><td>5.8&#x02009;&#x000b1;&#x02009;1.1</td><td>5.7&#x02009;&#x000b1;&#x02009;1.3</td><td>0.664</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec12"><title>Assessment of QoL</title><p id="Par19">Except for the insomnia item, there was no significant difference of baseline QoL between the groups (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). With respect to the EORTC QLQ-C30 items, no significant differences were identified between the two groups at the postoperative 3 months and 6 months. For insomnia, a better outcome was observed in the B-I group with difference about 7 points at postoperative 9 months; however, this difference turned to not significant at postoperative 1 year. At the postoperative 1 year time point, a higher score of global health status and a lower score of pain were detected in the R-Y group compared with the B-I group, which showed an overall average difference of 3 points and 6 points respectively. And R-Y group had showed a better trend for the dyspnea item without significant difference. The other scales, such as physical functioning, fatigue, diarrhea, and financial difficulties, were not significantly different between the two groups (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>, Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>).<table-wrap id="Tab3"><label>Table 3</label><caption><p>The preoperative and postoperative QoL of patients between the two groups according to the EORTC QLQ-C30 items.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">
<bold>Items</bold>
</th><th colspan="3">
<bold>Preoperative</bold>
</th><th colspan="3">
<bold>Postoperative 3 months</bold>
</th><th colspan="3">
<bold>Postoperative 6 months</bold>
</th><th colspan="3">
<bold>Postoperative 9 months</bold>
</th><th colspan="3">
<bold>Postoperative 1 year</bold>
</th></tr><tr><th>
<bold>B-I group</bold>
</th><th>
<bold>R-Y group</bold>
</th><th>
<bold>P</bold>
</th><th>
<bold>B-I group</bold>
</th><th>
<bold>R-Y group</bold>
</th><th>
<bold>P</bold>
</th><th>
<bold>B-I group</bold>
</th><th>
<bold>R-Y group</bold>
</th><th>
<bold>P</bold>
</th><th>
<bold>B-I group</bold>
</th><th>
<bold>R-Y group</bold>
</th><th>
<bold>P</bold>
</th><th>
<bold>B-I group</bold>
</th><th>
<bold>R-Y group</bold>
</th><th>
<bold>P</bold>
</th></tr></thead><tbody><tr><td>Physical functioning</td><td>93.1&#x02009;&#x000b1;&#x02009;7.9</td><td>93.4&#x02009;&#x000b1;&#x02009;8.3</td><td>0.710</td><td>92.4&#x02009;&#x000b1;&#x02009;11.8</td><td>91.3&#x02009;&#x000b1;&#x02009;10.8</td><td>0.430</td><td>95.2&#x02009;&#x000b1;&#x02009;8.8</td><td>96.6&#x02009;&#x000b1;&#x02009;6.9</td><td>0.356</td><td>93.9&#x02009;&#x000b1;&#x02009;9.5</td><td>96.3&#x02009;&#x000b1;&#x02009;8.8</td><td>0.073</td><td>96.7&#x02009;&#x000b1;&#x02009;7.3</td><td>97.5&#x02009;&#x000b1;&#x02009;7.5</td><td>0.339</td></tr><tr><td>Role functioning</td><td>93.4&#x02009;&#x000b1;&#x02009;12.9</td><td>91.4&#x02009;&#x000b1;&#x02009;16.7</td><td>0.966</td><td>90.4&#x02009;&#x000b1;&#x02009;15.9</td><td>90.4&#x02009;&#x000b1;&#x02009;15.3</td><td>0.916</td><td>94.4&#x02009;&#x000b1;&#x02009;13.1</td><td>94.9&#x02009;&#x000b1;&#x02009;12.6</td><td>0.929</td><td>92.4&#x02009;&#x000b1;&#x02009;13.3</td><td>94.4&#x02009;&#x000b1;&#x02009;11.4</td><td>0.459</td><td>96.3&#x02009;&#x000b1;&#x02009;10.3</td><td>99.0&#x02009;&#x000b1;&#x02009;4.0</td><td>0.124</td></tr><tr><td>Cognitive functioning</td><td>89.2&#x02009;&#x000b1;&#x02009;17.5</td><td>90.9&#x02009;&#x000b1;&#x02009;13.0</td><td>0.795</td><td>96.8&#x02009;&#x000b1;&#x02009;8.8</td><td>97.3&#x02009;&#x000b1;&#x02009;7.9</td><td>0.932</td><td>96.1&#x02009;&#x000b1;&#x02009;10.0</td><td>98.0&#x02009;&#x000b1;&#x02009;7.4</td><td>0.121</td><td>95.3&#x02009;&#x000b1;&#x02009;12.2</td><td>96.8&#x02009;&#x000b1;&#x02009;10.1</td><td>0.448</td><td>97.1&#x02009;&#x000b1;&#x02009;10.0</td><td>98.3&#x02009;&#x000b1;&#x02009;7.1</td><td>0.379</td></tr><tr><td>Emotional functioning</td><td>83.9&#x02009;&#x000b1;&#x02009;20.0</td><td>83.1&#x02009;&#x000b1;&#x02009;15.4</td><td>0.319</td><td>96.2&#x02009;&#x000b1;&#x02009;8.7</td><td>95.3&#x02009;&#x000b1;&#x02009;10.2</td><td>0.773</td><td>96.2&#x02009;&#x000b1;&#x02009;8.7</td><td>97.1&#x02009;&#x000b1;&#x02009;7.6</td><td>0.613</td><td>94.7&#x02009;&#x000b1;&#x02009;11.6</td><td>96.1&#x02009;&#x000b1;&#x02009;9.7</td><td>0.502</td><td>95.2&#x02009;&#x000b1;&#x02009;11.2</td><td>96.4&#x02009;&#x000b1;&#x02009;8.6</td><td>0.857</td></tr><tr><td>Social functioning</td><td>86.3&#x02009;&#x000b1;&#x02009;20.3</td><td>85.3&#x02009;&#x000b1;&#x02009;19.9</td><td>0.799</td><td>95.3&#x02009;&#x000b1;&#x02009;10.3</td><td>95.1&#x02009;&#x000b1;&#x02009;12.6</td><td>0.621</td><td>96.3&#x02009;&#x000b1;&#x02009;10.7</td><td>97.1&#x02009;&#x000b1;&#x02009;10.8</td><td>0.572</td><td>96.8&#x02009;&#x000b1;&#x02009;9.7</td><td>95.6&#x02009;&#x000b1;&#x02009;14.0</td><td>0.767</td><td>98.0&#x02009;&#x000b1;&#x02009;6.8</td><td>97.3&#x02009;&#x000b1;&#x02009;12.4</td><td>0.557</td></tr><tr><td>Global Health status</td><td>66.3&#x02009;&#x000b1;&#x02009;27.3</td><td>61.2&#x02009;&#x000b1;&#x02009;23.8</td><td>0.119</td><td>73.4&#x02009;&#x000b1;&#x02009;21.5</td><td>72.5&#x02009;&#x000b1;&#x02009;17.9</td><td>0.531</td><td>80.0&#x02009;&#x000b1;&#x02009;20.3</td><td>80.0&#x02009;&#x000b1;&#x02009;17.8</td><td>0.760</td><td>80.6&#x02009;&#x000b1;&#x02009;18.3</td><td>84.2&#x02009;&#x000b1;&#x02009;18.3</td><td>0.174</td><td>85.4&#x02009;&#x000b1;&#x02009;13.1</td><td>88.8&#x02009;&#x000b1;&#x02009;16.1</td><td>0.033</td></tr><tr><td>Pain</td><td>18.6&#x02009;&#x000b1;&#x02009;20.5</td><td>21.8&#x02009;&#x000b1;&#x02009;17.1</td><td>0.143</td><td>19.4&#x02009;&#x000b1;&#x02009;25.0</td><td>13.2&#x02009;&#x000b1;&#x02009;15.9</td><td>0.382</td><td>12.7&#x02009;&#x000b1;&#x02009;18.5</td><td>7.6&#x02009;&#x000b1;&#x02009;11.7</td><td>0.235</td><td>12.7&#x02009;&#x000b1;&#x02009;19.1</td><td>6.6&#x02009;&#x000b1;&#x02009;11.9</td><td>0.078</td><td>10.0&#x02009;&#x000b1;&#x02009;13.9</td><td>4.2&#x02009;&#x000b1;&#x02009;9.7</td><td>0.004</td></tr><tr><td>Fatigue</td><td>17.0&#x02009;&#x000b1;&#x02009;17.6</td><td>16.0&#x02009;&#x000b1;&#x02009;16.6</td><td>0.814</td><td>13.2&#x02009;&#x000b1;&#x02009;14.1</td><td>11.3&#x02009;&#x000b1;&#x02009;13.4</td><td>0.401</td><td>10.5&#x02009;&#x000b1;&#x02009;14.5</td><td>10.0&#x02009;&#x000b1;&#x02009;14.1</td><td>0.757</td><td>11.3&#x02009;&#x000b1;&#x02009;16.0</td><td>8.8&#x02009;&#x000b1;&#x02009;13.5</td><td>0.340</td><td>9.3&#x02009;&#x000b1;&#x02009;14.9</td><td>7.0&#x02009;&#x000b1;&#x02009;13.3</td><td>0.319</td></tr><tr><td>Nausea and vomiting</td><td>9.6&#x02009;&#x000b1;&#x02009;19.8</td><td>10.3&#x02009;&#x000b1;&#x02009;15.0</td><td>0.395</td><td>6.4&#x02009;&#x000b1;&#x02009;12.2</td><td>6.1&#x02009;&#x000b1;&#x02009;11.1</td><td>0.839</td><td>2.0&#x02009;&#x000b1;&#x02009;6.1</td><td>3.7&#x02009;&#x000b1;&#x02009;8.6</td><td>0.207</td><td>5.4&#x02009;&#x000b1;&#x02009;15.1</td><td>4.4&#x02009;&#x000b1;&#x02009;10.6</td><td>0.852</td><td>2.7&#x02009;&#x000b1;&#x02009;8.9</td><td>2.0&#x02009;&#x000b1;&#x02009;6.8</td><td>0.752</td></tr><tr><td>Insomnia</td><td>19.6&#x02009;&#x000b1;&#x02009;23.9</td><td>8.8&#x02009;&#x000b1;&#x02009;15.9</td><td>0.004</td><td>8.8&#x02009;&#x000b1;&#x02009;16.9</td><td>5.9&#x02009;&#x000b1;&#x02009;14.0</td><td>0.277</td><td>9.8&#x02009;&#x000b1;&#x02009;19.2</td><td>6.4&#x02009;&#x000b1;&#x02009;16.5</td><td>0.253</td><td>12.3&#x02009;&#x000b1;&#x02009;6.4</td><td>19.9&#x02009;&#x000b1;&#x02009;16.5</td><td>0.031</td><td>8.3&#x02009;&#x000b1;&#x02009;16.7</td><td>3.9&#x02009;&#x000b1;&#x02009;12.3</td><td>0.064</td></tr><tr><td>Appetite loss</td><td>11.3&#x02009;&#x000b1;&#x02009;22.0</td><td>12.3&#x02009;&#x000b1;&#x02009;19.0</td><td>0.487</td><td>6.9&#x02009;&#x000b1;&#x02009;13.6</td><td>9.3&#x02009;&#x000b1;&#x02009;17.1</td><td>0.488</td><td>8.3&#x02009;&#x000b1;&#x02009;16.7</td><td>4.9&#x02009;&#x000b1;&#x02009;13.2</td><td>0.176</td><td>5.9&#x02009;&#x000b1;&#x02009;14.0</td><td>4.4&#x02009;&#x000b1;&#x02009;14.0</td><td>0.341</td><td>4.9&#x02009;&#x000b1;&#x02009;13.2</td><td>2.5&#x02009;&#x000b1;&#x02009;10.5</td><td>0.153</td></tr><tr><td>Constipation</td><td>7.8&#x02009;&#x000b1;&#x02009;14.2</td><td>10.8&#x02009;&#x000b1;&#x02009;18.6</td><td>0.470</td><td>6.9&#x02009;&#x000b1;&#x02009;15.8</td><td>3.4&#x02009;&#x000b1;&#x02009;11.7</td><td>0.131</td><td>3.4&#x02009;&#x000b1;&#x02009;11.7</td><td>2.5&#x02009;&#x000b1;&#x02009;8.8</td><td>0.737</td><td>4.4&#x02009;&#x000b1;&#x02009;15.1</td><td>3.4&#x02009;&#x000b1;&#x02009;10.2</td><td>0.841</td><td>2.9&#x02009;&#x000b1;&#x02009;11.1</td><td>1.5&#x02009;&#x000b1;&#x02009;6.9</td><td>0.458</td></tr><tr><td>Diarrhea</td><td>8.3&#x02009;&#x000b1;&#x02009;15.6</td><td>11.8&#x02009;&#x000b1;&#x02009;19.8</td><td>0.322</td><td>7.8&#x02009;&#x000b1;&#x02009;17.4</td><td>11.8&#x02009;&#x000b1;&#x02009;19.8</td><td>0.173</td><td>10.3&#x02009;&#x000b1;&#x02009;21.7</td><td>9.8&#x02009;&#x000b1;&#x02009;20.8</td><td>0.966</td><td>6.9&#x02009;&#x000b1;&#x02009;14.7</td><td>6.4&#x02009;&#x000b1;&#x02009;14.4</td><td>0.828</td><td>6.9&#x02009;&#x000b1;&#x02009;14.7</td><td>7.8&#x02009;&#x000b1;&#x02009;19.2</td><td>0.897</td></tr><tr><td>Dyspnea</td><td>3.4&#x02009;&#x000b1;&#x02009;10.2</td><td>4.4&#x02009;&#x000b1;&#x02009;11.4</td><td>0.596</td><td>6.4&#x02009;&#x000b1;&#x02009;16.5</td><td>2.9&#x02009;&#x000b1;&#x02009;9.5</td><td>0.259</td><td>4.9&#x02009;&#x000b1;&#x02009;15.5</td><td>2.5&#x02009;&#x000b1;&#x02009;10.5</td><td>0.336</td><td>6.4&#x02009;&#x000b1;&#x02009;14.4</td><td>3.9&#x02009;&#x000b1;&#x02009;13.5</td><td>0.149</td><td>3.4&#x02009;&#x000b1;&#x02009;11.7</td><td>0.5&#x02009;&#x000b1;&#x02009;4.0</td><td>0.053</td></tr><tr><td>Financial difficulties</td><td>22.1&#x02009;&#x000b1;&#x02009;31.9</td><td>21.6&#x02009;&#x000b1;&#x02009;28.1</td><td>0.822</td><td>5.9&#x02009;&#x000b1;&#x02009;15.2</td><td>6.9&#x02009;&#x000b1;&#x02009;16.8</td><td>0.673</td><td>4.9&#x02009;&#x000b1;&#x02009;11.9</td><td>4.9&#x02009;&#x000b1;&#x02009;15.5</td><td>0.641</td><td>5.4&#x02009;&#x000b1;&#x02009;12.4</td><td>5.4&#x02009;&#x000b1;&#x02009;16.9</td><td>0.510</td><td>8.8&#x02009;&#x000b1;&#x02009;20.5</td><td>4.9&#x02009;&#x000b1;&#x02009;16.6</td><td>0.149</td></tr></tbody></table></table-wrap>
<fig id="Fig2"><label>Figure 2</label><caption><p>Comparison of QoL scores from preoperative baseline to postoperative 1 year between the two groups. (<bold>A</bold>) Pain item in QLQ-C30 questionnaire; (<bold>B</bold>) Global Health Status in QLQ-C30 questionnaire; (<bold>C</bold>) Pain item in QLQ-STO22 questionnaire; (<bold>D</bold>) Reflux symptom item in QLQ-STO22 questionnaire.</p></caption><graphic xlink:href="41598_2017_9676_Fig2_HTML" id="d29e2233"/></fig>
</p><p id="Par20">The scores of physical functioning, role functioning and global health status increased; while the scores of pain, nausea and vomiting showed decreased trends from the postoperative 3 months to the postoperative 1 year. However, there were no significant variations of other scales accompanied with the time trend. The multivariable analyses of variance did not show any interactions between the time trend and grouping, which meant that the variation of each scale accompanied with the time trend did not depend on the grouping (Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">S1</xref>, supporting information).</p><p id="Par21">Regarding to the QLQ-STO22 items, R-Y anastomosis was associated with lower incidence of reflux symptoms at postoperative 6 months (P&#x02009;=&#x02009;0.002) and postoperative 9 months (P&#x02009;=&#x02009;0.007). However, these differences discontinued to postoperative 1 year. A significant lower score of pain was noted in the R-Y group at postoperative 1 year (P&#x02009;=&#x02009;0.008). However, there were no significant differences on symptoms such as dysphagia, eating restrictions, having a dry mouth, change of taste, anxiety, body image and hair loss (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>, Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>).<table-wrap id="Tab4"><label>Table 4</label><caption><p>The preoperative and postoperative QoL of patients between the two groups according to the EORTC QLQ-STO22 items.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">
<bold>Items</bold>
</th><th colspan="3">
<bold>Preoperative</bold>
</th><th colspan="3">
<bold>Postoperative 3 months</bold>
</th><th colspan="3">
<bold>Postoperative 6 months</bold>
</th><th colspan="3">
<bold>Postoperative 9 months</bold>
</th><th colspan="3">
<bold>Postoperative 1 year</bold>
</th></tr><tr><th>
<bold>B-I group</bold>
</th><th>
<bold>R-Y group</bold>
</th><th>
<bold>P</bold>
</th><th>
<bold>B-I group</bold>
</th><th>
<bold>R-Y group</bold>
</th><th>
<bold>P</bold>
</th><th>
<bold>B-I group</bold>
</th><th>
<bold>R-Y group</bold>
</th><th>
<bold>P</bold>
</th><th>
<bold>B-I group</bold>
</th><th>
<bold>R-Y group</bold>
</th><th>
<bold>P</bold>
</th><th>
<bold>B-I group</bold>
</th><th>
<bold>R-Y group</bold>
</th><th>
<bold>P</bold>
</th></tr></thead><tbody><tr><td>Dysphagia</td><td>4.7&#x02009;&#x000b1;&#x02009;9.5</td><td>5.6&#x02009;&#x000b1;&#x02009;10.2</td><td>0.736</td><td>6.4&#x02009;&#x000b1;&#x02009;12.6</td><td>7.0&#x02009;&#x000b1;&#x02009;11.2</td><td>0.529</td><td>4.2&#x02009;&#x000b1;&#x02009;11.4</td><td>3.4&#x02009;&#x000b1;&#x02009;7.5</td><td>0.993</td><td>6.4&#x02009;&#x000b1;&#x02009;11.6</td><td>4.4&#x02009;&#x000b1;&#x02009;9.6</td><td>0.481</td><td>3.1&#x02009;&#x000b1;&#x02009;8.3</td><td>3.4&#x02009;&#x000b1;&#x02009;9.6</td><td>0.861</td></tr><tr><td>Pain</td><td>21.4&#x02009;&#x000b1;&#x02009;15.3</td><td>25.0&#x02009;&#x000b1;&#x02009;14.0</td><td>0.160</td><td>20.8&#x02009;&#x000b1;&#x02009;19.5</td><td>17.8&#x02009;&#x000b1;&#x02009;16.5</td><td>0.348</td><td>16.4&#x02009;&#x000b1;&#x02009;15.8</td><td>12.1&#x02009;&#x000b1;&#x02009;12.9</td><td>0.105</td><td>15.4&#x02009;&#x000b1;&#x02009;17.8</td><td>11.4&#x02009;&#x000b1;&#x02009;14.5</td><td>0.174</td><td>11.8&#x02009;&#x000b1;&#x02009;12.7</td><td>6.1&#x02009;&#x000b1;&#x02009;8.8</td><td>0.008</td></tr><tr><td>Reflux symptom</td><td>14.5&#x02009;&#x000b1;&#x02009;19.1</td><td>16.2&#x02009;&#x000b1;&#x02009;15.4</td><td>0.218</td><td>16.8&#x02009;&#x000b1;&#x02009;20.6</td><td>11.4&#x02009;&#x000b1;&#x02009;15.0</td><td>0.262</td><td>14.2&#x02009;&#x000b1;&#x02009;16.9</td><td>6.4&#x02009;&#x000b1;&#x02009;11.2</td><td>0.002</td><td>13.7&#x02009;&#x000b1;&#x02009;16.2</td><td>6.2&#x02009;&#x000b1;&#x02009;10.8</td><td>0.007</td><td>10.3&#x02009;&#x000b1;&#x02009;15.0</td><td>4.4&#x02009;&#x000b1;&#x02009;6.7</td><td>0.084</td></tr><tr><td>Eating restrictions</td><td>8.8&#x02009;&#x000b1;&#x02009;13.4</td><td>8.9&#x02009;&#x000b1;&#x02009;11.5</td><td>0.651</td><td>5.9&#x02009;&#x000b1;&#x02009;10.1</td><td>6.3&#x02009;&#x000b1;&#x02009;10.9</td><td>0.878</td><td>6.3&#x02009;&#x000b1;&#x02009;11.2</td><td>3.2&#x02009;&#x000b1;&#x02009;6.9</td><td>0.094</td><td>5.8&#x02009;&#x000b1;&#x02009;11.1</td><td>4.2&#x02009;&#x000b1;&#x02009;9.2</td><td>0.487</td><td>2.9&#x02009;&#x000b1;&#x02009;7.0</td><td>2.3&#x02009;&#x000b1;&#x02009;5.7</td><td>0.772</td></tr><tr><td>Having a dry mouth</td><td>16.2&#x02009;&#x000b1;&#x02009;23.4</td><td>19.6&#x02009;&#x000b1;&#x02009;21.0</td><td>0.192</td><td>4.4&#x02009;&#x000b1;&#x02009;11.4</td><td>7.8&#x02009;&#x000b1;&#x02009;16.4</td><td>0.231</td><td>7.4&#x02009;&#x000b1;&#x02009;15.1</td><td>5.4&#x02009;&#x000b1;&#x02009;12.4</td><td>0.486</td><td>6.9&#x02009;&#x000b1;&#x02009;13.6</td><td>8.3&#x02009;&#x000b1;&#x02009;17.6</td><td>0.802</td><td>6.9&#x02009;&#x000b1;&#x02009;15.8</td><td>6.9&#x02009;&#x000b1;&#x02009;18.7</td><td>0.688</td></tr><tr><td>Taste</td><td>8.8&#x02009;&#x000b1;&#x02009;17.9</td><td>5.9&#x02009;&#x000b1;&#x02009;14.0</td><td>0.291</td><td>6.4&#x02009;&#x000b1;&#x02009;14.4</td><td>7.8&#x02009;&#x000b1;&#x02009;15.4</td><td>0.527</td><td>6.9&#x02009;&#x000b1;&#x02009;17.8</td><td>5.4&#x02009;&#x000b1;&#x02009;12.4</td><td>0.940</td><td>5.9&#x02009;&#x000b1;&#x02009;15.2</td><td>8.3&#x02009;&#x000b1;&#x02009;16.7</td><td>0.286</td><td>6.4&#x02009;&#x000b1;&#x02009;13.2</td><td>5.9&#x02009;&#x000b1;&#x02009;17.2</td><td>0.402</td></tr><tr><td>Anxiety</td><td>17.8&#x02009;&#x000b1;&#x02009;20.3</td><td>18.6&#x02009;&#x000b1;&#x02009;19.7</td><td>0.650</td><td>6.7&#x02009;&#x000b1;&#x02009;12.3</td><td>9.2&#x02009;&#x000b1;&#x02009;15.7</td><td>0.309</td><td>5.9&#x02009;&#x000b1;&#x02009;11.3</td><td>6.9&#x02009;&#x000b1;&#x02009;14.3</td><td>0.946</td><td>10.0&#x02009;&#x000b1;&#x02009;15.7</td><td>7.0&#x02009;&#x000b1;&#x02009;14.5</td><td>0.230</td><td>9.3&#x02009;&#x000b1;&#x02009;15.9</td><td>6.9&#x02009;&#x000b1;&#x02009;13.8</td><td>0.281</td></tr><tr><td>Body image</td><td>5.9&#x02009;&#x000b1;&#x02009;14.0</td><td>6.9&#x02009;&#x000b1;&#x02009;15.8</td><td>0.794</td><td>2.0&#x02009;&#x000b1;&#x02009;7.9</td><td>3.9&#x02009;&#x000b1;&#x02009;10.8</td><td>0.228</td><td>3.4&#x02009;&#x000b1;&#x02009;10.2</td><td>3.4&#x02009;&#x000b1;&#x02009;10.2</td><td>1.000</td><td>4.9&#x02009;&#x000b1;&#x02009;11.9</td><td>4.9&#x02009;&#x000b1;&#x02009;13.2</td><td>0.834</td><td>3.4&#x02009;&#x000b1;&#x02009;11.7</td><td>2.5&#x02009;&#x000b1;&#x02009;8.8</td><td>0.737</td></tr><tr><td>Hair loss</td><td>5.4&#x02009;&#x000b1;&#x02009;10.9</td><td>6.1&#x02009;&#x000b1;&#x02009;12.5</td><td>0.738</td><td>2.2&#x02009;&#x000b1;&#x02009;8.6</td><td>2.9&#x02009;&#x000b1;&#x02009;9.9</td><td>0.737</td><td>3.7&#x02009;&#x000b1;&#x02009;10.3</td><td>2.2&#x02009;&#x000b1;&#x02009;8.6</td><td>0.269</td><td>0.74&#x02009;&#x000b1;&#x02009;4.5</td><td>2.0&#x02009;&#x000b1;&#x02009;6.8</td><td>0.15</td><td>2.5&#x02009;&#x000b1;&#x02009;9.7</td><td>2.0&#x02009;&#x000b1;&#x02009;9.3</td><td>0.525</td></tr></tbody></table></table-wrap>
</p><p id="Par22">The dysphagia, pain, reflux symptoms and eating restrictions became better from the postoperative 3 months to the postoperative 1 year. However, these trends were not observed in other scales. The multivariable analyses of variance also demonstrated no interaction between the time trend and grouping (Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">S2</xref>, supporting information).</p></sec><sec id="Sec13"><title>Endoscopic findings</title><p id="Par23">No significant differences were found in terms of food residual and bile reflux between the two groups. However, the severity of remnant gastritis was milder significantly in the R-Y group, compared with the B-I group. There was only 32.6% of patients in the B-I group suffering from gastritis less than grade 2. The corresponding percentage in the R-Y group was 58.7% (Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref>).<table-wrap id="Tab5"><label>Table 5</label><caption><p>The results of endoscopic evaluation at postoperative 12 months according to the &#x0201c;residue, gastritis, bile&#x0201d; classification.</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>B-I group N&#x02009;=&#x02009;46 (%)</th><th>R-Y group N&#x02009;=&#x02009;46 (%)</th><th>P Value</th></tr></thead><tbody><tr><td>
<bold>Food Residual</bold>
</td><td/><td/><td>0.749</td></tr><tr><td>Grade 0</td><td>34 (73.9)</td><td>33 (71.7)</td><td/></tr><tr><td>Grade 1</td><td>5 (10.9)</td><td>4 (8.7)</td><td/></tr><tr><td>Grade 2</td><td>2 (4.3)</td><td>3 (6.5)</td><td/></tr><tr><td>Grade 3</td><td>4 (8.7)</td><td>4 (8.7)</td><td/></tr><tr><td>Grade 4</td><td>1 (2.2)</td><td>2 (4.3)</td><td/></tr><tr><td>
<bold>Degree of Gastritis</bold>
</td><td/><td/><td>0.025</td></tr><tr><td>Grade 0</td><td>8 (17.4)</td><td>19 (41.3)</td><td/></tr><tr><td>Grade 1</td><td>7 (15.2)</td><td>8 (17.4)</td><td/></tr><tr><td>Grade 2</td><td>19 (41.3)</td><td>10 (21.7)</td><td/></tr><tr><td>Grade 3</td><td>7 (15.2)</td><td>4 (8.7)</td><td/></tr><tr><td>Grade 4</td><td>5 (10.9)</td><td>5 (10.9)</td><td/></tr><tr><td>
<bold>Extent of Gastritis</bold>
</td><td/><td/><td>0.016</td></tr><tr><td>Grade 0</td><td>8 (17.4)</td><td>19 (41.3)</td><td/></tr><tr><td>Grade 1</td><td>7 (15.2)</td><td>7 (15.2)</td><td/></tr><tr><td>Grade 2</td><td>25 (54.3)</td><td>16 (34.8)</td><td/></tr><tr><td>Grade 3</td><td>6 (13.0)</td><td>4 (8.7)</td><td/></tr><tr><td>
<bold>Bile reflux</bold>
</td><td/><td/><td>0.137</td></tr><tr><td>Grade 0</td><td>37 (80.4)</td><td>42 (91.3)</td><td/></tr><tr><td>Grade 1</td><td>9 (19.6)</td><td>4 (8.7)</td><td/></tr></tbody></table></table-wrap>
</p></sec></sec><sec id="Sec14" sec-type="discussion"><title>Discussion</title><p id="Par24">Our results showed that there was no perioperative mortality in either group, and the morbidity and postoperative recovery were comparable between the two groups. However, the estimated blood loss and surgical duration were significantly less in the B-I group, which was accordance with the previous reports. One multicenter RCT in Japan found that there was 34&#x02009;minutes longer of average operation time in the R-Y group than B-I group, but the overall morbidity were not significantly different (13.6% vs. 8.6%)<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>. Kitagami <italic>et al</italic>. also observed the similar results in the cohorts with laparoscopic distal gastrectomy<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>. The technical-simplicity of B-I anastomosis, which has only one anastomosis and the exemption of duodenal stump handling compared with R-Y group, might attribute to the less blood loss and operation time. However, Ishikawa and Kojima <italic>et al</italic>. demonstrated that there were no significant differences in terms of operation time and blood loss between the two groups, either in open surgery or laparoscopic surgery<sup><xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR15">15</xref></sup>. These discrepancies could be partly explained by the different operative habits of surgeons, procedures of anastomoses (e.g. hand-sewn or stapling) and surgical instruments (e.g. linear or circular stapler). Some previous researches pointed out that there might be a higher possibility of anastomotic leakage in the B-I anastomosis<sup><xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR25">25</xref></sup>, which was associated with the impaired blood supply of duodenal stump and excessive tension of anastomotic site<sup><xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR25">25</xref></sup>. However, there were no anastomosis related complications in the present study. Two cases of intraperitoneal infections were observed in the R-Y group, which might be caused by a longer exposure of digestive tract since longer operation time and more anastomosis were needed.</p><p id="Par25">The R-Y stasis syndrome, which is characterized by the stasis symptoms of upper gastrointestinal tract after R-Y anastomosis, might be induced by an ectopic pace which arises from the proximal part of the Roux limb after the division of small intestine and separates the normal pace from the duodenum<sup><xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref></sup>. Ishikawa <italic>et al</italic>. found that 20.8% of patients in the R-Y group developed stasis in the early postoperative period<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>. Otsuka <italic>et al</italic>. also demonstrated that 11.6% of patients experienced R-Y stasis syndrome<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>. Therefore, some surgeons advocated to perform the uncut R-Y anastomosis, in order to keep the continuity of digestive tract and decrease the incidence of R-Y stasis syndrome<sup><xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref></sup>. Nevertheless, the results remained inconsistent even though the uncut R-Y anastomosis was performed. The reason might be not only the continuity of digestive tract, but also the vagus nerve was divided in the operation for gastric cancer. In our study, however, there was only 1 patient suffering from stasis in each group and no significant differences were found in terms of food residual between the two groups, which was consistent with other reports<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>.</p><p id="Par26">Quality of life has been regarded as an important outcome measurement parameter and emphasized in cancer patients. If the same oncological outcomes could be achieved, the postoperative QoL would be an influence factor of the selection of surgical procedures. The clinical practicability and validity of EORTC QLQ-C30 and stomach module QLQ-STO22 questionnaires to assess the QoL of patients with gastric cancer have been proven in many studies<sup><xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR31">31</xref>&#x02013;<xref ref-type="bibr" rid="CR33">33</xref></sup>, including the Chinese version of QLQ-C30 and QLQ-STO22 for Chinese patients<sup><xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref></sup>.</p><p id="Par27">The present study found that physical functioning, role functioning and global health improved while pain, nausea and vomiting, dysphagia, pain, reflux symptoms and eating restrictions attenuated from the postoperative 3 months to 1 year. Furthermore, these variations accompanied with the time trend did not depend on the grouping. These results suggested that the removal of tumor could improve the QoL and alleviate the digestive symptoms. Moreover, these improvements were independent on the anastomotic methods, which was supported by the findings of Katagami&#x02019;s study<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>. At the same time, our study showed that the change of QoL could continue to the postoperative 1 year even longer. Nakamura <italic>et al</italic>. also found that symptom scales at 12 months were not significantly different, but were significantly better in the B-I group at 36 months after gastrectomy<sup><xref ref-type="bibr" rid="CR34">34</xref></sup>. These were different from the previous studies indicating that the postoperative 6 months was a cut-point of QoL<sup><xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR36">36</xref></sup>.</p><p id="Par28">Regarding the reflux symptom, many studies have showed that R-Y anastomosis could reduce the reflux symptom and reflux-related gastritis and esophagitis, and improve the QoL accordingly<sup><xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR37">37</xref>&#x02013;<xref ref-type="bibr" rid="CR39">39</xref></sup>. In this study, we also noticed a decreased incidence of reflux symptom in the R-Y group at postoperative 6 months and 9 months. As time went by, however, the differences of QoL between the two groups diminished. Therefore, there were no statistical differences between the two groups at postoperative 1 year although still better in the R-Y group. In fact, the endoscopic examination found no significant difference in terms of reflux between the two groups at postoperative 1 year. Nevertheless, the degree and extent of remnant gastritis were milder in the R-Y group since more severe reflux has already existed in the B-I group for a long time.</p><p id="Par29">Our results showed that the R-Y group had a marginal better control of dyspnea symptom (P&#x02009;=&#x02009;0.053). The Japanese RCT also found the superior dyspnea symptom scale in the R-Y group<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>. However, the authors considered that this symptom seemed to be physiologically unrelated to postoperative complications<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>. Insomnia was also considered more as psychological issues than physiological ones<sup><xref ref-type="bibr" rid="CR40">40</xref></sup>. This may be one of the reasons why the scores of insomnia item fluctuated.</p><p id="Par30">Pain is a kind of subjective feeling, which is influenced by many factors, such as postoperative intraperitoneal adhesions<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>, the incidence and severity of reflux symptom and cholelithiasis <italic>etc</italic>. Mathias <italic>et al</italic>. demonstrated that the pain symptoms was the secondary to a defect in motor function of Roux limb and could be observed almost in all the patients undergoing R-Y reconstruction<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>. Takiguchi <italic>et al</italic>. showed that there was no significant difference in terms of pain scale until postoperative 3 years between the two kinds of anastomoses<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>. Nunobe <italic>et al</italic>. also reported that no significant difference on pain was noted between the B-I group and R-Y group at postoperative 5 years<sup><xref ref-type="bibr" rid="CR37">37</xref></sup>. However, the present study found that R-Y anastomosis could result in milder pain significantly at postoperative 1 year, which might benefit from the alleviated reflux-related remnant gastritis. Decreased reflux and pain could contribute to a better global health status at postoperative 1 year in the R-Y group.</p><p id="Par31">There are some limitations of this study. Firstly, the QoL data was obtained by questionnaires, which was a kind of subjective data and easy to be biased by patients&#x02019; feeling, cultural background and educational level. Although inevitable in the studies about QoL, using questionnaires to evaluate the QoL is an internationally accepted research approach. Secondly, our interim analysis only reported the 1 year results of this study. We would continue to follow up the patients and evaluate the long-term QoL. Furthermore, more outcome measurements including anemia, stone of gallbladder and long-term survival would be reported in the future. Finally, although being a popular reconstruction method after distal gastrectomy, the Billroth-II anastomosis was considered to be inferior to its counterparts in terms of the postoperative complications, anti-reflux capability and potential risk of remnant gastric cancer<sup><xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR39">39</xref></sup>. Therefore, the Billroth-II anastomosis was not considered in the design of the trial.</p><p id="Par32">In conclusion, both B-I and R-Y anastomosis are safe and feasible which could be applied in the clinical practice. The stronger anti-reflux capability of R-Y anastomosis contributes to a higher QoL by reducing the reflux related gastritis and pain symptoms, and promoting a better global health.</p></sec><sec sec-type="supplementary-material"><title>Electronic supplementary material</title><sec id="Sec15"><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41598_2017_9676_MOESM1_ESM.pdf"><caption><p>Supplementary Information</p></caption></media></supplementary-material>
</p></sec></sec></body><back><fn-group><fn><p>Kun Yang and Wei-Han Zhang contributed equally to this work.</p></fn><fn><p>A correction to this article is available online at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/s41598-018-24612-8">https://doi.org/10.1038/s41598-018-24612-8</ext-link>.</p></fn><fn><p><bold>Electronic supplementary material</bold></p><p>
<bold>Supplementary information</bold> accompanies this paper at doi:10.1038/s41598-017-09676-2
</p></fn><fn><p>
<bold>Publisher's note:</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>This work was internal supported by Volunteer Team of Gastric Cancer Surgery (VOLTGA), West China Hospital, Sichuan University, P.R.China. The authors thank Dr. Li-Fei Sun (Department of Gastrointestinal Surgery, West China Hospital, China), for his kind language modification of the manuscript. Domestic support from (1) National Natural Science Foundation of China (No. 81301867, 81372344); (2) Sichuan Province Youth Science &#x00026; Technology Innovative Research Team (No. 2015TD0009); (3) 1. 3. 5 project for disciplines of excellence, West China Hospital, Sichuan University; (4) The Scientific Research Program of Public Health Department of Sichuan Province, China (No. 120196).</p></ack><notes notes-type="author-contribution"><title>Author Contributions</title><p>Study conception and design: Yang, Zhang, Chen, Hu; Acquisition of data: Yang, Zhang, Liu, Chen; Analysis and interpretation of data: Yang, Zhang, Zhou, Hu; Drafting of manuscript: Yang; Critical revision: Yang, Zhang, Hu.</p></notes><notes notes-type="COI-statement"><sec id="FPar1"><title>Competing Interests</title><p id="Par33">The authors declare that they have no competing interests.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torre</surname><given-names>LA</given-names></name><etal/></person-group><article-title>Global cancer statistics, 2012</article-title><source>CA Cancer J Clin</source><year>2015</year><volume>65</volume><fpage>87</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.3322/caac.21262</pub-id><pub-id pub-id-type="pmid">25651787</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colquhoun</surname><given-names>A</given-names></name><etal/></person-group><article-title>Global patterns of cardia and non-cardia gastric cancer incidence in 2012</article-title><source>Gut</source><year>2015</year><volume>64</volume><fpage>1881</fpage><lpage>1888</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2014-308915</pub-id><pub-id pub-id-type="pmid">25748648</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Songun</surname><given-names>I</given-names></name><name><surname>Putter</surname><given-names>H</given-names></name><name><surname>Kranenbarg</surname><given-names>EM</given-names></name><name><surname>Sasako</surname><given-names>M</given-names></name><name><surname>van de Velde</surname><given-names>CJ</given-names></name></person-group><article-title>Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial</article-title><source>Lancet Oncol</source><year>2010</year><volume>11</volume><fpage>439</fpage><lpage>449</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(10)70070-X</pub-id><pub-id pub-id-type="pmid">20409751</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noh</surname><given-names>SH</given-names></name><etal/></person-group><article-title>CLASSIC trial investigators. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial</article-title><source>Lancet Oncol</source><year>2014</year><volume>15</volume><fpage>1389</fpage><lpage>1396</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(14)70473-5</pub-id><pub-id pub-id-type="pmid">25439693</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bang</surname><given-names>YJ</given-names></name><etal/></person-group><article-title>ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial</article-title><source>Lancet</source><year>2010</year><volume>376</volume><fpage>687</fpage><lpage>697</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(10)61121-X</pub-id><pub-id pub-id-type="pmid">20728210</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richter</surname><given-names>JE</given-names></name></person-group><article-title>Duodenogastric reflux-induced (alkaline) esophagitis</article-title><source>Curr Treat Options Gastroenterol</source><year>2004</year><volume>7</volume><fpage>53</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1007/s11938-004-0025-1</pub-id><pub-id pub-id-type="pmid">14723838</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fein</surname><given-names>M</given-names></name><etal/></person-group><article-title>Duodenoesophageal reflux induces esophageal adenocarcinoma without exogenous carcinogen</article-title><source>J Gastrointest Surg</source><year>1998</year><volume>2</volume><fpage>260</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.1016/S1091-255X(98)80021-8</pub-id><pub-id pub-id-type="pmid">9841983</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fukuhara</surname><given-names>K</given-names></name><etal/></person-group><article-title>Reconstructive procedure after distal gastrectomy for gastric cancer that best prevents duodenogastroesophageal reflux</article-title><source>World J Surg</source><year>2002</year><volume>26</volume><fpage>1452</fpage><lpage>1457</lpage><pub-id pub-id-type="doi">10.1007/s00268-002-6363-z</pub-id><pub-id pub-id-type="pmid">12370787</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathias</surname><given-names>JR</given-names></name><name><surname>Fernandez</surname><given-names>A</given-names></name><name><surname>Sninsky</surname><given-names>CA</given-names></name><name><surname>Clench</surname><given-names>MH</given-names></name><name><surname>Davis</surname><given-names>RH</given-names></name></person-group><article-title>Nausea, vomiting, and abdominal pain after Roux-en-Y anastomosis: motility of the jejuna limb</article-title><source>Gastroenterology</source><year>1985</year><volume>88</volume><fpage>101</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1016/S0016-5085(85)80140-2</pub-id><pub-id pub-id-type="pmid">3964759</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woodward</surname><given-names>A</given-names></name><name><surname>Sillin</surname><given-names>LF</given-names></name><name><surname>Wojtowycz</surname><given-names>AR</given-names></name><name><surname>Bortoff</surname><given-names>A</given-names></name></person-group><article-title>Gastric stasis of solids after Roux gastrectomy: is the jejunal transection important?</article-title><source>J Surg Res</source><year>1993</year><volume>55</volume><fpage>317</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.1006/jsre.1993.1148</pub-id><pub-id pub-id-type="pmid">8412117</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishikawa</surname><given-names>M</given-names></name><etal/></person-group><article-title>Prospective randomized trial comparing Billroth I and Roux-en-Y procedures after distal gastrectomy for gastric carcinoma</article-title><source>World J Surg</source><year>2005</year><volume>29</volume><fpage>1415</fpage><lpage>1421</lpage><pub-id pub-id-type="doi">10.1007/s00268-005-7830-0</pub-id><pub-id pub-id-type="pmid">16240061</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Namikawa</surname><given-names>T</given-names></name><etal/></person-group><article-title>Roux-en-Y reconstruction is superior to billroth I reconstruction in reducing reflux esophagitis after distal gastrectomy: special relationship with the angle of his</article-title><source>World J Surg</source><year>2010</year><volume>34</volume><fpage>1022</fpage><lpage>1027</lpage><pub-id pub-id-type="doi">10.1007/s00268-010-0452-1</pub-id><pub-id pub-id-type="pmid">20143067</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imamura</surname><given-names>H</given-names></name><etal/></person-group><article-title>Morbidity and mortality results from a prospective randomized controlled trial comparing Billroth I and Roux-en-Y reconstructive procedures after distal gastrectomy for gastric cancer</article-title><source>World J Surg</source><year>2012</year><volume>36</volume><fpage>632</fpage><lpage>637</lpage><pub-id pub-id-type="doi">10.1007/s00268-011-1408-9</pub-id><pub-id pub-id-type="pmid">22270979</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takiguchi</surname><given-names>S</given-names></name><etal/></person-group><article-title>Osaka University Clinical Research Group for Gastroenterological Study. A comparison of postoperative quality of life and dysfunction after Billroth I and Roux-en-Y reconstruction following distal gastrectomy for gastric cancer: results from a multi-institutional RCT</article-title><source>Gastric Cancer</source><year>2012</year><volume>15</volume><fpage>198</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1007/s10120-011-0098-1</pub-id><pub-id pub-id-type="pmid">21993852</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kojima</surname><given-names>K</given-names></name><name><surname>Yamada</surname><given-names>H</given-names></name><name><surname>Inokuchi</surname><given-names>M</given-names></name><name><surname>Kawano</surname><given-names>T</given-names></name><name><surname>Sugihara</surname><given-names>K</given-names></name></person-group><article-title>A comparison of Roux-en-Y and Billroth-I reconstruction after laparoscopy-assisted distal gastrectomy</article-title><source>Ann Surg</source><year>2008</year><volume>247</volume><fpage>962</fpage><lpage>967</lpage><pub-id pub-id-type="doi">10.1097/SLA.0b013e31816d9526</pub-id><pub-id pub-id-type="pmid">18520223</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kitagami</surname><given-names>H</given-names></name><etal/></person-group><article-title>Evaluation of the delta-shaped anastomosis in laparoscopic distal gastrectomy: midterm results of a comparison with Roux-en-Y anastomosis</article-title><source>Surg Endosc</source><year>2014</year><volume>28</volume><fpage>2137</fpage><lpage>2144</lpage><pub-id pub-id-type="doi">10.1007/s00464-014-3445-6</pub-id><pub-id pub-id-type="pmid">24515263</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>K</given-names></name><etal/></person-group><article-title>Strategies to improve treatment outcome in gastric cancer: A retrospective analysis of patients from two high-volume hospitals in Korea and China</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><fpage>44660</fpage><lpage>44675</lpage><pub-id pub-id-type="pmid">27191995</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Japanese Gastric Cancer Association</collab></person-group><article-title>Japanese classification of gastric carcinoma: 3rd English edition</article-title><source>Gastric Cancer</source><year>2011</year><volume>14</volume><fpage>101</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1007/s10120-011-0041-5</pub-id><pub-id pub-id-type="pmid">21573743</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Japanese gastric cancer association</collab></person-group><article-title>Japanese gastric cancer treatment guidelines 2010 (ver. 3)</article-title><source>Gastric Cancer</source><year>2011</year><volume>14</volume><fpage>113</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1007/s10120-011-0042-4</pub-id><pub-id pub-id-type="pmid">21573742</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Quality of life following laparoscopic-assisted distal gastrectomy for gastric cancer</article-title><source>Hepatogastroenterology</source><year>2012</year><volume>59</volume><fpage>2207</fpage><lpage>2212</lpage><pub-id pub-id-type="pmid">22282128</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="other">Fayers, P. M. <italic>et al</italic>. On behalf of the EORTC Quality of Life Group. The EORTC QLQ-C30 Scoring Manual (3rd Edition). European Organization for Research and Treatment of Cancer; Brussels, (2001).</mixed-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vickery</surname><given-names>CW</given-names></name><etal/></person-group><article-title>Development of an EORTC disease-specific quality of life module for use in patients with gastric cancer</article-title><source>Eur J Cancer</source><year>2001</year><volume>37</volume><fpage>966</fpage><lpage>971</lpage><pub-id pub-id-type="doi">10.1016/S0959-8049(00)00417-2</pub-id><pub-id pub-id-type="pmid">11334720</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clavien</surname><given-names>PA</given-names></name><etal/></person-group><article-title>The Clavien-Dindo classification of surgical complications: five-year experience</article-title><source>Ann Surg</source><year>2009</year><volume>250</volume><fpage>187</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1097/SLA.0b013e3181b13ca2</pub-id><pub-id pub-id-type="pmid">19638912</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kubo</surname><given-names>M</given-names></name><etal/></person-group><article-title>Endoscopic evaluation of the remnant stomach after gastrectomy: proposal for a new classification</article-title><source>Gastric Cancer</source><year>2002</year><volume>5</volume><fpage>83</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1007/s101200200014</pub-id><pub-id pub-id-type="pmid">12111583</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujiwara</surname><given-names>M</given-names></name><etal/></person-group><article-title>Laparoscopy-assisted distal gastrectomy with systemic lymph node dissection for early gastric carcinoma: a review of 43 cases</article-title><source>J Am Coll Surg</source><year>2003</year><volume>196</volume><fpage>75</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1016/S1072-7515(02)01539-9</pub-id><pub-id pub-id-type="pmid">12517554</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morrison</surname><given-names>P</given-names></name><name><surname>Miedema</surname><given-names>BW</given-names></name><name><surname>Kohler</surname><given-names>L</given-names></name><name><surname>Kelly</surname><given-names>KA</given-names></name></person-group><article-title>Electrical dysrhythmias in the Roux jejunal limb: cause and treatment</article-title><source>Am J Surg</source><year>1990</year><volume>160</volume><fpage>252</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.1016/S0002-9610(06)80017-6</pub-id><pub-id pub-id-type="pmid">2393051</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miedema</surname><given-names>BW</given-names></name><name><surname>Kelly</surname><given-names>KA</given-names></name></person-group><article-title>The Roux stasis syndrome. Treatment by pacing and prevention by use of an &#x02018;uncut&#x02019; Roux limb</article-title><source>Arch Surg</source><year>1992</year><volume>127</volume><fpage>295</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1001/archsurg.1992.01420030057011</pub-id><pub-id pub-id-type="pmid">1489374</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Otsuka</surname><given-names>R</given-names></name><name><surname>Natsume</surname><given-names>T</given-names></name><name><surname>Maruyama</surname><given-names>T</given-names></name><name><surname>Tanaka</surname><given-names>H</given-names></name><name><surname>Matsuzaki</surname><given-names>H</given-names></name></person-group><article-title>Antecolic reconstruction is a predictor of the occurrence of roux stasis syndrome after distal gastrectomy</article-title><source>J Gastrointest Surg</source><year>2015</year><volume>19</volume><fpage>821</fpage><lpage>824</lpage><pub-id pub-id-type="doi">10.1007/s11605-015-2770-y</pub-id><pub-id pub-id-type="pmid">25693423</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>JY</given-names></name><name><surname>Kim</surname><given-names>YJ</given-names></name></person-group><article-title>Uncut Roux-en-Y Reconstruction after Laparoscopic Distal Gastrectomy Can Be a Favorable Method in Terms of Gastritis, Bile Reflux, and Gastric Residue</article-title><source>J Gastric Cancer</source><year>2014</year><volume>14</volume><fpage>229</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.5230/jgc.2014.14.4.229</pub-id><pub-id pub-id-type="pmid">25580354</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yun</surname><given-names>SC</given-names></name><name><surname>Choi</surname><given-names>HJ</given-names></name><name><surname>Park</surname><given-names>JY</given-names></name><name><surname>Kim</surname><given-names>YJ</given-names></name></person-group><article-title>Total laparoscopic uncut Roux-en-Y gastrojejunostomy after distal gastrectomy</article-title><source>Am Surg</source><year>2014</year><volume>80</volume><fpage>E51</fpage><lpage>E53</lpage><pub-id pub-id-type="pmid">24480200</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aaronson</surname><given-names>NK</given-names></name><etal/></person-group><article-title>The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology</article-title><source>J Natl Cancer Inst</source><year>1993</year><volume>85</volume><fpage>365</fpage><lpage>376</lpage><pub-id pub-id-type="doi">10.1093/jnci/85.5.365</pub-id><pub-id pub-id-type="pmid">8433390</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>C</given-names></name><etal/></person-group><article-title>Validation of the simplified Chinese version of EORTC QLQ-C30 from the measurements of five types of inpatients with cancer</article-title><source>Ann Oncol</source><year>2008</year><volume>19</volume><fpage>2053</fpage><lpage>2060</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdn417</pub-id><pub-id pub-id-type="pmid">18653703</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>CC</given-names></name><name><surname>Lien</surname><given-names>HH</given-names></name><name><surname>Sung</surname><given-names>YC</given-names></name><name><surname>Liu</surname><given-names>HT</given-names></name><name><surname>Chie</surname><given-names>WC</given-names></name></person-group><article-title>Quality of life of patients with gastric cancer in Taiwan: validation and clinical application of the Taiwan Chinese version of the EORTC QLQ-C30 and EORTC QLQ-STO22</article-title><source>Psychooncology</source><year>2007</year><volume>16</volume><fpage>945</fpage><lpage>949</lpage><pub-id pub-id-type="doi">10.1002/pon.1158</pub-id><pub-id pub-id-type="pmid">17279609</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>M</given-names></name><etal/></person-group><article-title>Randomized clinical trial comparing long-term quality of life for Billroth I versus Roux-en-Y reconstruction after distal gastrectomy for gastric cancer</article-title><source>Br J Surg</source><year>2016</year><volume>103</volume><fpage>337</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.1002/bjs.10060</pub-id><pub-id pub-id-type="pmid">26840944</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zieren</surname><given-names>HU</given-names></name><name><surname>Jacobi</surname><given-names>CA</given-names></name><name><surname>Zieren</surname><given-names>J</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>JM</given-names></name></person-group><article-title>Quality of life following resection of oesophageal carcinoma</article-title><source>Br J Surg</source><year>1996</year><volume>83</volume><fpage>1772</fpage><lpage>1775</lpage><pub-id pub-id-type="doi">10.1002/bjs.1800831235</pub-id><pub-id pub-id-type="pmid">9038566</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barbour</surname><given-names>AP</given-names></name><etal/></person-group><article-title>Health-related quality of life among patients with adenocarcinoma of the gastro-oesophageal junction treated by gastrectomy or oesophagectomy</article-title><source>Br J Surg</source><year>2008</year><volume>95</volume><fpage>80</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1002/bjs.5912</pub-id><pub-id pub-id-type="pmid">17849373</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nunobe</surname><given-names>S</given-names></name><etal/></person-group><article-title>Billroth 1 versus Roux-en-Y reconstructions: a quality-of-life survey at 5 years</article-title><source>Int J Clin Oncol</source><year>2007</year><volume>12</volume><fpage>433</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.1007/s10147-007-0706-6</pub-id><pub-id pub-id-type="pmid">18071862</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zong</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>P</given-names></name></person-group><article-title>Billroth I vs. Billroth II vs. Roux-en-Y following distal gastrectomy: a meta-analysis based on 15 studies</article-title><source>Hepatogastroenterology</source><year>2011</year><volume>58</volume><fpage>1413</fpage><lpage>1424</lpage><pub-id pub-id-type="doi">10.5754/hge10567</pub-id><pub-id pub-id-type="pmid">21937419</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>MS</given-names></name><etal/></person-group><article-title>What is the best reconstruction method after distal gastrectomy for gastric cancer?</article-title><source>Surg Endosc</source><year>2012</year><volume>26</volume><fpage>1539</fpage><lpage>1547</lpage><pub-id pub-id-type="doi">10.1007/s00464-011-2064-8</pub-id><pub-id pub-id-type="pmid">22179454</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomaszewski</surname><given-names>KA</given-names></name><etal/></person-group><article-title>Main influencing factors and health-related quality of life issues in patients with oesophago-gastric cancer - as measured by EORTC tools</article-title><source>Contemp Oncol (Pozn)</source><year>2013</year><volume>17</volume><fpage>311</fpage><lpage>316</lpage><pub-id pub-id-type="pmid">24596521</pub-id></element-citation></ref></ref-list></back></article>